Immune response to hepatitis B virus antigens

The immune response to hepatitis B virus antigens encompasses the coordinated activity of innate and adaptive immune cells (including dendritic cells, natural killer cells, B cells, and T lymphocytes) in recognizing, responding to, and attempting to eliminate HBV antigens presented by infected hepatocytes. These responses are crucial for controlling infection but can also lead to chronic inflammation, tissue damage, and the risk of liver pathology. HBV has evolved mechanisms to evade immune detection, resulting in persistent infection or reactivation. Therapies often aim to enhance, restore, or modulate these immune responses for improved viral control and liver health. “Immune response to hepatitis B virus antigens” should not be considered a canonical drug target but rather a complex biological process involving multiple immune molecules and cells. For structured database purposes, this entry should be flagged as incorrect or too broad. To identify actionable targets, individual components (e.g., interferon-alpha receptor, programmed cell death protein 1, hepatitis B surface antigen) should be considered.

Other names

Immune response to hepatitis B virusImmune response to HBV antigens

Mechanisms targeting this process include: Enhancement or modulation of innate or adaptive immune activity; Reduction of viral antigen presentation via viral replication inhibition; Blockade of immune checkpoint pathways (experimental, aimed at reversing T cell exhaustion)